Anti-amyloid monoclonal antibodies represent a transformative approach to disease-modifying therapy for Alzheimer's disease (AD). These therapeutics target various forms of amyloid-beta (Abeta) plaques and oligomers, aiming to remove pathological amyloid deposits and slow cognitive decline. Four antibodies have undergone extensive clinical development: [lecanemab](/entities/lecanemab), [donanemab](/entities/donanemab), gantenerumab, and solanezumab. This page provides a comprehensive comparison of their clinical trial designs, efficacy data, safety profiles, and patient selection criteria.
Mechanism of Action Comparison
Lecanemab
Lecanemab selectively binds to soluble Aβ protofibrils, which are believed to be the most toxic form of amyloid species. Protofibrils are intermediate aggregates that are more soluble than plaques but exhibit high neurotoxicity. By targeting protofibrils, lecanemab can neutralize soluble toxic species while also promoting clearance of deposited plaques[@van2023].
Donanemab
Donanemab preferentially binds to pyroglutamate-modified Aβ (N3pG-Aβ), an epitope that is enriched in deposited plaques rather than soluble monomers. This plaque-targeting mechanism leads to robust amyloid plaque removal through microglial-mediated phagocytosis[@sims2023].
Gantenerumab
Gantenerumab is a fully human IgG1 antibody that binds to aggregated Aβ in both oligomeric and fibrillar forms. It engages the Fcγ receptor pathway on [microglia](/cell-types/microglia-neuroinflammation), triggering antibody-mediated phagocytosis of amyloid plaques[@bateman2023].
Solanezumab
Solanezumab was designed to bind to the central domain of soluble Aβ monomers, promoting peripheral clearance of Aβ from the brain. However, its failure to meaningfully clear plaques or slow cognitive decline in multiple Phase 3 trials suggests that targeting soluble monomers alone is insufficient for clinical benefit[@salloway2023].
Clinical Trial Designs
Phase 3 Trials Overview
Patient Population Comparison
Key Design Differences
Tau Selection: Donanemab's TRAILBLAZER-ALZ 2 specifically enrolled patients with low-to-medium tau pathology, excluding those with high tau burden. This enrichment strategy may have contributed to its stronger efficacy signals.
Disease Stage: The A4 trial enrolled cognitively normal individuals with preclinical AD, making it unique as a secondary prevention trial. All other trials focused on early symptomatic disease.
Treatment Duration: CLARITY-AD and TRAILBLAZER-ALZ 2 were 18-month trials, while GRADUATE was 2 years.
Clinical Efficacy Data
Primary Endpoint Results
Amyloid Plaque Removal
Biomarker Changes
All antibodies that successfully removed amyloid plaques showed downstream biomarker effects:
Reduced CSF p-tau181: Consistent across lecanemab, donanemab, and gantenerumab trials, suggesting slowed tau pathology
Reduced CSF t-tau: Observed with amyloid clearance
Brain volume changes: Mixed results; some antibodies showed slower hippocampal atrophy, while others showed transient ARIA-related effects
Safety Profiles
Amyloid-Related Imaging Abnormalities (ARIA)
ARIA is the most significant safety concern with anti-amyloid antibodies. It manifests as:
ARIA-E (edema): Fluid accumulation in the brain, visible on MRI as hyperintense T2/FLAIR signals
ARIA-H (hemorrhage): Microhemorrhages or superficial siderosis
Risk Factors for ARIA
[APOE](/proteins/apoe) ε4 carrier status: Higher risk, especially homozygous carriers